Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of more than 100 pathologist-verified Maxpar® antibodies for use with Imaging Mass Cytome...
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm serving the life science tools market, recognized Fluidigm (NASDAQ:FLDM) with the Gold Award for the Best New Product in Cell Biology for the Maxpar® Di...
Fluidigm ( FLDM -3.4% ) prices its private offering of 5.25% convertible senior notes due 2024 at par. The initial conversion rate is 344.8276 common shares per $1,000 principal amount of the notes (~$2.90 per share). More news on: Fluidigm Corporation, Healthcare stocks news, Stocks o...
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount ...
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it intends to offer, subject to market conditions and other ...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in the 31st...
Already reeling from a tumbling stock price, Fluidigm (NASDAQ: FLDM) investors were shocked by the company's latest quarterly report. The laboratory hardware developer, supposedly in the midst of a promising growth trajectory, reported a year-over-year decline in total revenue in the third q...
Fluidigm (NASDAQ: FLDM) Q3 2019 Earnings Call Nov 05, 2019 , 5:00 p.m. ET Operator Ladies and gentlemen, thank you for standing by, and welcome to Fluidigm third-quarter 2019 financial results. [Operator instructions] As a reminder, this conference call is being recorded. I ...
Gainers: Constellation Pharmaceuticals (NASDAQ: CNST ) +99% . More news on: Constellation Pharmaceuticals, Inc., FuelCell Energy, Inc., comScore, Inc., Stocks on the move, Read more ...
Shares of Fluidigm (NASDAQ: FLDM) fell more than 54% on Wednesday after the company reported third-quarter 2019 operating results. The lab instrument developer, supposedly in the midst of a growth spurt, reported that revenue declined compared with the year-ago period. Worse yet, the segme...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...